Patent: 4,704,273
✉ Email this page to a colleague
Summary for Patent: 4,704,273
Title: | Methods and materials for treatment of rheumatoid arthritis |
Abstract: | Disclosed are methods and compositions useful for alleviating the symptoms of rheumatoid arthritis. In preferred embodiments, the compositions are administered in essentially minute \"neutralizing\" doses. The compositions comprise mixtures of histamine, immunoglobulin G provocative of RF formation or an immunologically active fraction thereof, collagen and either attenuated measles virus or immunologically active fraction thereof. Illustratively significant relief of symptoms of arthritis disease symptoms is achieved through parenteral (e.g., subcutaneous or sublingual) administration of such compositions. |
Inventor(s): | McMichael; John (Cambridge Springs, PA) |
Assignee: | |
Application Number: | 06/833,998 |
Patent Claims: | see list of patent claims |
Details for Patent 4,704,273
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Csl Behring Ag | CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN | immune globulin intravenous (human) | For Injection | 102367 | 07/27/2000 | ⤷ Try a Trial | 2040-01-28 |
Alk-abello, Inc. | HISTATROL | positive skin test control-histamine | Injection | 103754 | 09/29/1950 | ⤷ Try a Trial | 2040-01-28 |
Jubilant Hollisterstier Llc | N/A | positive skin test control-histamine | Injection | 103891 | 03/13/1924 | ⤷ Try a Trial | 2040-01-28 |
Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | 07/26/2007 | ⤷ Try a Trial | 2040-01-28 |
Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | 10/02/2009 | ⤷ Try a Trial | 2040-01-28 |
Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | 02/07/2013 | ⤷ Try a Trial | 2040-01-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |